Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Bone Oncology Année : 2020

Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers

Résumé

As for molecular alterations of lung adenocarcinoma, it is critical that pathologists are able to give PD-L1 expression status before first-line of treatment. The present study compared PD-L1 expression (clone 22-C3) in decalcified using EDTA or formic acid and non-decalcified lung cancer metastases bone samples. Amongst the 84 bone samples analysed for PD-L1 expression, and independently of decalcification, TPS ≥ 1% was 25.0% and ≥ 50% was 11.4%. There was no significant difference between decalcified samples (n = 45) and non-decalcified samples (n = 39) for both TPS ≥ 1% (p = 0.32) and TPS ≥ 50% (p = 1). To conclude, we confirm decalcified bone metastasis specimens may be used for PD-L1 IHC in routine practice. These results also highlight potentially interesting specificities of the bone microenvironment that should be further studied.
Fichier principal
Vignette du fichier
S221213741930212X.pdf (2.06 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02929279 , version 1 (21-07-2022)

Licence

Identifiants

Citer

Guillaume Pontarollo, Cyrille B Confavreux, Jean-Baptiste Pialat, Sylvie Isaac, Fabien F Forest, et al.. Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers. Journal of Bone Oncology, 2020, 21, pp.100275. ⟨10.1016/j.jbo.2020.100275⟩. ⟨hal-02929279⟩
31 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More